GH — Guardant Health, Inc.

Is GH overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Neutral As of August 19, 2026

Guardant Health, Inc. (GH) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $163.34. The rating moved from Overbought to Neutral on August 12, 2026.

AI analysis

Guardant Health is a leading liquid‑biopsy provider with a strong product franchise and data assets that support recurring commercial and clinical-trial revenue. Demand drivers include broader adoption of molecular diagnostics in oncology and upgrades to diagnostic pathways, which align with recent sector themes. Financially the company has demonstrated revenue growth but remains unprofitable, with operating cash burn and potential need for access to capital if margins do not improve. Primary near-term upside hinges on reimbursement progress, continued adoption in clinical practice and trial partnerships; downside is driven by payer resistance, competitive pressures, and execution/regulatory setbacks. Near-term market conditions appear steady, supporting stability while fundamental catalysts play out over the next several quarters.

Key factors

  • Market-leading position in oncology liquid biopsy with recognized brand (Guardant360) and expanding test menu that drives recurring lab-service revenue.
  • Sector tailwinds for diagnostics and screening (oncology imaging/biopsy pathway upgrades) that can increase referral volumes and testing demand.
  • Commercial partnerships and growing adoption across oncology care pathways and clinical trials (CDx and trial-enabling assays) support medium-term revenue visibility.
  • Technology and data assets (genomic database, assay development) create differentiation versus smaller competitors and can enable higher-margin products over time.
  • Recent market environment showing balanced risk appetite; lack of macro shocks in the short window supports near-term stability in share trading.

Risks

  • Reimbursement uncertainty and payer pushback on price/take rates for liquid biopsy tests, which can materially impact revenue and gross margins.
  • Intense competition from other diagnostics firms (including large integrated players) and from tissue-based assays and alternative liquid-biopsy approaches.
  • Continued operating losses and cash burn that may require capital raises if execution slips; dilution risk on equity financing.
  • Regulatory and clinical-evidence risk if prospective utility data or label/coverage developments are slower or less favorable than expected.
  • Procedure-volume sensitivity: slower adoption of screening programs or declines in interventional procedures could reduce test volumes.
  • Valuation and sentiment volatility typical for growth diagnostics names, which can amplify share-price moves independent of fundamentals.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for GH — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.